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Abstract. Incidentally discovered adrenal masses are detected in 0.35% to
5.00% of patients imaged with computed tomography (CT) for reasons
other than suspected adrenal pathology. Most small adrenal masses are
benign, although malignant tumors < 3 cm in diameter are well de-
scribed. In the setting of normal adrenal hormonal secretion, the prefer-
ential accumulation of 131I-6b-iodomethyl-norcholesterol (NP59) by ad-
renocortical tissues allows the distinction of adenomas from other
space-occupying or destructive lesions, with diagnostic images being
obtained in 100% of lesions > 2 cm. Although some lesions < 2 cm have
yielded nondiagnostic images, the frequency of this phenomenon and thus
the utility of NP59 scintigraphy for the evaluation of small adrenal lesions
has remained incompletely characterized. Between January 1976 and
December 1994 a total of 166 patients with nonhypersecretory unilateral
adrenal masses < 3 cm in maximal diameter, discovered incidentally
during CT examinations of the abdomen or chest for reasons other than
clinically suspected adrenal disease, were studied with NP59 scintigraphy.
Nonhypersecretory masses < 1 cm, > 1 to < 2 cm, and > 2 to < 3 cm
yielded diagnostic images in 52%, 89%, and 100% of patients, respectively.
Lesions other than adenomas, including malignancies, > 1 to < 2 cm
and > 2 to < 3 cm were present in 9% and 10% of patients, respectively.
These findings emphasize the need to determine the nature of small
incidentally discovered adrenal masses whose management may alter
patient care and confirm the utility of NP59 scintigraphy to evaluate
nonhypersecretory adrenal masses regardless of size.
The likelihood of malignant incidentally discovered adrenal
masses (incidentalomas) rises with increasing diameter [1]. How-
ever, in the absence of known extraadrenal primary malignancy,
benign adrenal masses outnumber malignant masses regardless of
size [1]. Furthermore, malignant neoplasms must be small at some
time in their development, and some benign masses may become
large. Adrenal malignancies , 3 cm are well described [1]. The
large incidentally discovered adrenal mass (. 3 cm in diameter)
poses little difficulty for anatomic characterization with computed
tomography (CT) or magnetic resonance imaging (MRI), func-
tional characterization with adrenocortical scintigraphy or
positron emission tomography (PET), or tissue characterization
by CT-guided adrenal biopsy [1, 2]. Smaller masses (# 3 cm in
diameter) may pose greater difficulty. Yet determination of their
etiology remains no less important, as subsequent critical clinical
and diagnostic decisions may be based on the presence or absence
of primary adrenal malignancy, metastatic disease in the adre-
nal(s), or the presence of some adrenal lesions other than simple
nonhypersecretory adenomas.
We have previously noted that the frequency of diagnostically
useful imaging patterns is reduced when lesions # 2 cm are
studied scintigraphically, but the regularity of this occurrence and
thus the relation of lesion diameter to sensitivity of 131I-6b-
iodomethyl-norcholesterol (NP59) imaging have not been docu-
mented in detail. Thus when faced with the problem of a small
nonhypersecretory adrenal mass, the utility of adrenal scintigra-
phy has remained incompletely characterized. In this paper we
report our experience with the scintigraphic characterization of
small (# 3 cm in diameter) incidentally discovered euadrenal
masses.
Materials and Methods
Between January 1976 and December 1994 a total of 166 patients
with unilateral adrenal masses discovered incidentally during CT
examination of the abdomen or chest performed for reasons other
than clinically suspected adrenal disease were studied with NP59
scintigraphy. CT was initially performed with an EMI-5005 and
later with a Picker 1200SX at the VAMedical Center, Ann Arbor,
and with a GE-8800 or GE-9800 scanner at the University of
Michigan Medical Center. Contiguous 5- to 10-mm sections were
obtained on the newer scanners after intravenous or oral radio-
graphic contrast administration.
All patients referred for NP59 scintigraphy gave written in-
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formed consent for the study that was approved by each hospital’s
Institutional Review Board for Human Experimentation. NP59 (1
mCi) was injected intravenously followed by posterior, usually
lateral and occasionally anterior, abdominal scans (at least 50,000
counts per image) performed one or more times between days 5
and 10 after injection. Saturated potassium iodide solution (SSKI)
was begun 24 to 48 hours prior to radiopharmaceutical adminis-
tration and continued for 14 days to suppress thyroid uptake of
free 131I. A mild laxative (bisacodyl 10 mg once or twice daily by
mouth) was also given to most patients, beginning 2 days before
the first day of imaging, to reduce potentially interfering colonic
131I radioactivity [3].
For each patient various combinations of blood and urine
biochemical measurements were obtained to exclude the presence
of adrenal cortical and medullary hypersecretion. They included
normal plasma levels of cortisol; urinary free cortisol excretion;
plasma renin activity; serum or urine (or both) aldosterone,
potassium, epinephrine, norepinephrine, metanephrine, and
normetanephrine; urinary 17-hydroxycorticosteroids and 17-ke-
tosteroids; serum dehydroepiandrosterone (DHEA), dehydroepi-
androsterone sulfate (DHEAS), or both; urinary vanillylmandelic
acid (VMA); normal cortisol response to dexamethasone; and in
some cases normal serum cortisol response to intravenous adre-
nocorticotropic hormone (ACTH) administration. Medications
that might interfere with the scintigraphic or biochemical studies
were discontinued prior to investigation [1, 2]. Certain features of
some cases (138 patients) have been included (in a different
context) in reports of adrenal masses in patients with preexisting
malignancy [4] and in large series on the use of NP59 for
evaluation of adrenal masses of all sizes [5, 6]. Following NP59
scintigraphy and reevaluation of the CT scan, those cases that
proved to have pseudoadrenal or periadrenal masses, rather than
true adrenal mass lesions, have been excluded from consideration.
The correlation of relative NP59 uptake between the two
adrenals was assessed qualitatively based on previously estab-
lished criteria for normal adrenal NP59 uptake [7] and an
interpretative algorithm for incidentally discovered adrenal
masses (Table 1) [1].
Statistical analyses were performed using Student’s t-test and
the chi-square test.
Results
The indications for study with CT that initially demonstrated the
presence of an adrenal mass are listed in Table 2. There were 82
men and 84 women with a mean (6 SD) age of 59.0 6 11.5 years
(range 24–88 years). There were 76 right-sided and 90 left-sided
masses (chi-square not significant). The distribution of adrenal
masses as a function of their largest diameter estimated by CT is
shown in Table 3.
A final diagnosis of adenoma was made by adrenalectomy in 18
patients, CT-guided adrenal biopsy in 10, and no change in
adrenal appearance on repeat CT scans and clinical follow-up 6
months or more from the initial CT examination in the remaining
104 patients.
Fourteen intraadrenal space-occupying or destructive lesions
other than adenomas were detected and confirmed by CT-guided
adrenal biopsy or adrenalectomy. Metastatic lung carcinoma was
responsible for the masses in seven patients and adrenal cysts in
two patients; in the remaining five patients adrenal masses were
due to leukemia, metastatic colon adenocarcinoma, metastatic
renal carcinoma, pheochromocytoma, and an adrenal hematoma,
respectively. The results of NP59 scintigraphy are shown in Table
3.
Discussion
Scintigraphy with NP59 was diagnostic in 149 of 166 (90%) cases
(Figs. 1, 2). Normal (nonlateralizing) imaging patterns were
observed in 17 patients (10%) of whom 3 had adrenal metastases
(1.5, 1.8, and 2.0 cm in maximal diameter) and 14 had adenomas
(# 1 cm in 10 patients and . 1 to # 2 cm in maximal diameter in
4 patients).
Stratification of adrenal masses by size demonstrated a diag-
nostic pattern in all masses . 2 cm in maximal diameter.
However, an increasing number of nonlateralizing imaging pat-
terns was seen in progressively smaller masses: 7 of 64 (11%)
masses . 1 to # 2 cm and 10 of 21 (48%) masses # 1 cm in
diameter (Table 3).
Malignancy rates of adrenal masses in the setting of a known
extraadrenal primary malignancy have ranged from 32% to 73%,
and benign masses have been reported in 27% to 68% of cases [1].
Table 1. Nomenclature of adrenal scintigraphy for the characterization
of nonhypersecretory incidentalomas.
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Table 2. Indications for the computed tomography that revealed small
adrenal masses.
Indication for CT No. of cases
Staging of known or suspected malignancy 86
Abdominal pain 56
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In this setting, malignancy rates among those with adrenal
masses # 3 cm have ranged from 0% to 50%, whereas among
those with adrenal masses . 3 cm malignancy rates have ranged
from 43% to 100% [1]. Thus diagnostic algorithms based on size
alone miss a small but significant number of potentially clinically
important adrenal neoplasms.
Many authors advocate serial CT follow-up examinations and
suggest that a lesion stable in size is benign whereas those that
enlarge are malignant. This strategy is impractical for patients
with known extraadrenal malignancy who are being considered for
potentially curable resection of their primary tumors. The oppor-
tunity for cure may be lost in those primary adrenal malignancies
(cortical or medullary) diagnosed only after demonstration of
tumor growth, local invasion, or the appearance of local or distant
metastases. Serial CT examinations subject a large number of
patients with benign adenomas to unnecessary and expensive
follow-up imaging. Finally, the optimal interval and duration of
serial imaging protocols is unknown, during which time many
patients are lost to follow-up [1].
Thin-section (5 mm or less) unenhanced CT allows analysis of
tissue x-ray attenuation characteristics that appear to distinguish
benign from metastatic neoplasms better than size criteria alone
[1, 2]. An unenhanced CT attenuation coefficient of 0 Hounsfield
units (HU) or less has been reported as being 100% specific for
Fig. 1. CT examination performed to stage squamous cell
lung carcinoma disclosed a 1 cm diameter right adrenal mass
that yielded a concordant NP59 image pattern. A. CT scan
with oral and intravenous contrast demonstrates the right
adrenal mass (white arrow). B. Posterior abdominal NP59
scintiscan 5 days after radiotracer injection demonstrates
intense uptake in the right adrenal gland (large arrowhead)
and normal NP59 uptake in the left adrenal gland (small
arrowhead). The lesion remained stable on follow-up CT
examinations despite progression of the primary tumor and
development of distant nonadrenal metastases.
Fig. 2. CT examination performed for abdominal pain
disclosed a 2 cm in diameter left adrenal mass that yielded a
discordant NP59 image pattern. A. CT scan without contrast
demonstrates the left adrenal mass (white arrow). B.
Posterior abdominal NP59 scintiscan at 5 days after
radiotracer injection demonstrates normal uptake in the liver
(L) and decreased uptake in the left adrenal gland (large
arrowhead) compared to that of the normal right adrenal
gland (small arrowhead). The remaining peripheral foci
depict normal gastrointestinal radiotracer activity.
Subsequent CT-guided fine-needle biopsy demonstrated
leukemic infiltration of the left adrenal gland.



































# 1 21 11 0 10e — 100 (84–100)f 52 (30–74) 52 (30–74) —
. 1 to # 2 64 54 3 7g 30 (18–42) 100 (95–100) 89 (82–96) 89 (82–96) 100 (95–100)
. 2 to # 3 81 73 8 0 100 (95–100) 100 (95–100) 100 (95–100) 100 (95–100) 100 (95–100)
Total 166 138 11 17 39 (31–47) 100 (97–100) 90 (85–95) 89 (84–94) 100 (97–100)
aTP 5 True positive: discordant pattern for lesion other than an adenoma.
bFN 5 False negative: nonlateralizing pattern with a known intraadrenal lesion.
cTN 5 True negative: concordant pattern for an adenoma.
dFP 5 False positive: discordant pattern for an adenoma.
eAll adenomas.
fNinety-five percent confidence limits.
gThree lesions other than adenomas and four adenomas.
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benign adenomas versus metastasis; but given the high percentage
of adrenal adenomas with attenuation values . 0 HU, low
sensitivities of 33% and 47% have been reported [1]. Similarly, a
threshold of 10 HU results in a sensitivity of approximately 73%
and a specificity of 96% [2]. There appears, however, to be a
progressive decrease in the ability to accurately determine atten-
uation coefficients in decreasingly smaller masses, and thus effi-
cacy would be expected to diminish [8, 9].
A growing body of evidence supports the use of MRI for
characterizing adrenal incidentalomas [1, 2]. Intensity ratios of
normal tissue (usually liver or spleen) to adrenal lesions [1, 10]
and novel pulse sequences that provide some insight into the lipid
content of adrenal tissues can be shown to differentiate benign
from malignant masses with a sensitivity for detecting adenomas
of around 81% to 84% and a specificity near 100% [1, 2].
However, smaller adrenal masses may present problems, with
partial volume averaging with MRI leading to spurious tissue
signal results [11, 12]. Although most series include masses that
are as small as 10 mm, few report results stratified with respect to
mass diameter.
Positron emission tomography (PET) with 2-[fluorine-18]-
fluoro-2-deoxy-D-glucose (FDG) has been used to characterize
adrenal masses [1.5–10.0 cm in diameter (mean 2.8 cm)] in 20
patients with cancer [13]. PET tumor/background ratios [stan-
dardized uptake value (SUV)] correctly differentiated benign
from malignant lesions in all patients. However, patients with
adrenal masses , 1.5 cm in diameter were not included, and it is
estimated that the spatial resolution of PET is approximately 1 cm
(although possibly less for lesions with intense FDG uptake). This
remarkable separation of benign from malignant tumors has not
been duplicated by others.
Percutaneous adrenal biopsy under ultrasound or CT guidance
offers both high accuracy (80–100%) and specificity toward
differentiating benign lesions from metastases to the adrenal
glands [1]. In some series, however, all false-negative biopsies
(7%) were from lesions , 3 cm in greatest diameter [14].
Significant complications occur in 3% to 13% of cases [1, 14].
Percutaneous adrenal biopsy is considered relatively contraindi-
cated to differentiate benign adenomas from adrenocortical car-
cinomas given the low sensitivity (54–86%) and the low, but
possible, risk of seeding malignant cells along the needle tract in
an otherwise potentially curable patient [1, 2]. Because most small
adrenal masses are benign, biopsy or adrenalectomy of those
masses that exhibit characteristics compatible with malignancy
(i.e., a discordant imaging pattern on NP59 scintigraphy) would
optimize the selection of masses for these more invasive proce-
dures [1].
Adrenal scintigraphy has been used to distinguish benign from
malignant or space-occupying adrenal masses in euadrenal pa-
tients [1]. Although NP59 remains an investigational new drug
(IND) in the United States, it is available for investigative use
from the Nuclear Pharmacy at the University of Michigan Medical
Center after filing an abbreviated IND with the U. S. Food and
Drug Administration. Unilateral and bilateral adrenal masses can
be characterized according to function in the sense that the
mass(es) can or cannot accumulate the radiopharmaceutical (e.g.,
NP59) sufficient for in vivo scintigraphic imaging [1]. For unilat-
eral, nonhypersecretory adrenal masses, NP59 uptake that ex-
ceeds the anatomically normal contralateral adrenal gland (as
demonstrated by CT or MRI) would be considered benign (Fig.
1), whereas decreased or absent NP59 uptake in a mass seen on
CT or MRI would be compatible with some other space-occupy-
ing or destructive lesion (Fig. 2) [1]. Thus iodocholesterol scintig-
raphy can be used to select which adrenal masses would be the
best candidates for further (and likely invasive) diagnostic evalu-
ation.
The overall efficacy of adrenal scintigraphy for the evaluation of
euadrenal masses is high and exceeds that of both CT and MRI [1,
5, 6]. Previous studies have illustrated that the number of false-
negative NP59 studies increases with decreasing mass diameter [5,
6]. It is not surprising that for a mass to deform or destroy
sufficient adrenal cortex to be detected as a discordant imaging
pattern scintigraphically (“cold spot imaging”) size is an important
factor [5, 15]. The importance of size in relation to NP59 imaging
may be somewhat less critical for functioning masses, as their
iodocholesterol accumulation compared to that in the contralat-
eral anatomically normal adrenal gland more easily allows scinti-
graphic visualization (concordant imaging pattern; “hot spot
imaging”). This point is evidently true, as 54 of 58 (93%) adrenal
adenomas . 1 to # 2 cm in diameter demonstrated diagnostic
concordant patterns of imaging, whereas only 3 of 6 (50%) lesions
that were not adenomas in this same size range demonstrated the
characteristic discordant imaging pattern. The continued relative
importance of mass size for adrenal adenomas is demonstrated by
the fact that for masses # 1 cm in diameter the number of
false-negative studies is greater (10 of 21, 48%) than that seen in
masses . 1 to # 2 cm in diameter (4 of 58, 7%) (Table 3).
It is not surprising that sensitivity falls to 39% in the current
study for lesions # 3 cm; as the proportion of false-negative
studies increases, however, other parameters of efficacy remain
high. The “false-negative” group contained few malignant lesions
(3 of 17, 18%), and so the better measure of clinical utility is the
accuracy (90%), which denotes the probability of obtaining a
diagnostic image that has been 100% specific. Thus even with
masses # 1 cm, 52% of patients had diagnostic images. No
malignancies were present that were # 1 cm in diameter. It is not
surprising that this series contains no primary adrenocortical
carcinomas. Statistically, one would expect to find approximately
one primary adrenocortical carcinoma among each 10,000 to
500,000 adrenal incidentalomas # 5 cm in diameter [1, 16].
Although the prevalence of metastases for masses . 1 to # 2 cm
in diameter is low (6 of 64, 9%), it is not trivial. Thus regardless
of size, it remains possible to determine with high efficacy the
nature of many adrenal masses by the presence or absence of
NP59 uptake.
Lacking direct comparison, the decision as to which, if any,
modality should be used routinely to determine the nature of
small adrenal masses cannot be answered by the present study.
Preliminary data using formal decision analysis based on available
estimates of diagnostic performance and reimbursement costs,
suggests that NP59 scintigraphy is the most cost-effective diagnos-
tic tool to evaluate the adrenal incidentaloma [17].
Résumé
Les «incidentalomes» surrénaliens sont découverts chez 0.35 à 5%
des patients ayant eu une tomodensitométrie pour une pathologie
non surrénalienne. Alors que la plupart des masses de la surrénale
sont bénignes, on a décrit des tumeurs malignes de trois cm ou
moins. Lorsque l’hormonologie surrénalienne est normale,
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l’accumulation préférentielle de 131-I-6b-iodométhyl-nor-cholés-
terol (NP59) par la cortico-surrénale en scintigraphie permet de
distinguer les adénomes des autres lésions, les images étant
obtenues dans 100% des cas de lésions , 2 cm de diamètre.
Parfois cependant, des lésions de 2 cm ou moins ne
s’accompagnent d’aucune image. L’utilité de la scintigraphie
NP59 dans l’évaluation des lésions de la surrénale reste donc
incomplètement élucidée. Méthodes: Entre Janvier 1976 et Dé-
cembre 1994, 166 patients porteurs d’une masse surrénalienne
unilatérale non-hypersécrétoire de trois cm ou moins, découverte
de façon fortuite sur une tomodensitométrie de l’abdomen ou du
thorax, ont été évalués par la scintigraphie NP59. Résultats: Les
masses non-hypersécrétoires de diamètre # 1 cm, de . 1-# 2 cm,
et de. 2-# 3 cm ont fourni des images chez respectivement 52%,
89%, et 100% des patients. Les lésions autres que les adénomes,
y compris les lésions malignes . 1-# 2 cm et de . 2-# 3 cm, ont
été retrouvées, chez respectivement 9% et 10% des patients.
Conclusions: Ces données confirment le besoin de déterminer la
nature des masses surrénaliennes de découverte fortuite. Leur
traitement pourrait changer la prise en charge du patient. Une
scintigraphie NP59 permettrait d’évaluer la masse indépendam-
ment de sa taille.
Resumen
Antecedentes: Las masas suprarrenales que se descubren en
forma incidental ocurren en 0.35%–5% de los pacientes que son
sometidos a TAC por razones diferentes a la sospecha de
patologia adrenal. A unque la mayorı̀a de las masas adrenales
pequeñas son de caràcter benigno, tambièn ocurren tumores
malignos de A3 3 cm de diàmetro. En el contexto de secreciòn
normal de las hormonas adrenales, la concentraciòn preferencial
del 131-I-yodometil-norcolesterol (NP59) por los tejidos adreno-
corticales permite la diferenciaciòn entre adenomas y otras lesio-
nes que ocupan espacio que causan destrucciòn local, logràndose
una imagen adecuada en el 100% de las lesiones . 2 cm. A pesar
de que algunas lesiones A3 2 cm no resultan en una imagen
diagnòstica, la frecuencia de tal fenòmeno y, por consiguiente, la
utilidad de la escintigrafı̀a con NP59 en la valoraciòn de lesiones
adrenales de tamaño pequeño no ha sido completamente
definida. Mètodos: En el perı̀odo comprendido entre enero de
1976 y diciembre de 1994, se estudiaron 177 pacientes con masas
adrenales, con diàmetro màximo A3 3 cm, unilaterales, no
hipersecretoras, descubiertas incidentalmente en el curso de
exàmenes por TAC del abdomen o del tòrax, practicados por
razones diferentes de sospecha clı̀nica de enfermedad adrenal.
Resultados: Las masas no hipersecretoras de A3 1 cm, 1- A3 2 cm
y . 2 - A3 3 cm produjeron imagen diagnòstica en 52%, 89% y
100% de los pacientes, respectivamente. Se encontraron otras
lesiones diferentes de adenomas, incluso tumores malignos de .
1 - A3 2 cm, 0 . 2 - A33 cm en 9% y 10% de los pacientes,
respectivamente. Conclusiones: Nuestros hallazgos resaltan la
necesidad de determinar la naturaleza de las pequeñas masas
adrenales que sean descubiertas incidentalmente, cuyo trata-
miento puede implicar una modificaciòn en el manejo del paci-
ente y confirmar la utilidad de la escintigrafı̀a con NP59 en la
valoraciòn de las masas adrenales no hipersecretoras, no importa
cual sea su tamaño.
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